Propanc Biopharma, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Propanc Biopharma
Pharmaceutical Preparations, SIC 2834
The text does not contain factual narrative descriptions explaining what the company does, its main products or services, operating segments, or customers. The provided content consists exclusively of XBRL tags, member classifications, agreement references, and date ranges without any contextual business descriptions or operational disclosures.
Additionally, the excerpt provides no factual information concerning the company's scale, facilities, store counts, operating reach, or corporate headquarters. Although tags mention geographic identifiers for the United States and Australia, no narrative or factual statements in the text specify where the company conducts operations or where its headquarters are located.
Summary of the business section of Propanc Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Propanc Biopharma, Inc.
- Headquarters
- Camberwell, Victoria, C3
- Address
- 302/6 Butler Street 3124
- Phone
- 61-03-9882-0780
- Employees
- 2, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- SALBERG & COMPANY, P.A, Boca Raton, Florida
Stock & identifiers
- Ticker
- PPCB
- Exchange
- Nasdaq
- Shares outstanding
- 6M, Sep 23, 2026
- Public float
- $2.66M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, May 18, 2026; 1-for-59983 reverse, Feb 14, 2025; 1-for-2 reverse, Jan 29, 2025; 1-for-1000 reverse, Nov 19, 2020; 1-for-500 reverse, Oct 15, 2019; 1-for-500 reverse, Jun 24, 2019; 1-for-250 reverse, May 8, 2017; 1-for-250 reverse, Apr 20, 2017
- SEC CIK
- 1517681
- CUSIP
- 74346N800
- ISIN
- US74346N8002
- LEI
- 549300Q3HY827FNV8Y56
- EIN
- 33-0662986
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Propanc Biopharma's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had two full-time and employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 7, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 13, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
| Feb 14, 2024 | Late filing | Notification of late filing |
| Sep 29, 2020 | Late filing | Notification of late filing |
| Sep 30, 2019 | Late filing | Notification of late filing |
| Apr 5, 2017 | Name change | Name changed from Propanc Health Group Corp to Propanc Biopharma, Inc. |
| Sep 29, 2015 | Late filing | Notification of late filing |
| Nov 14, 2014 | Late filing | Notification of late filing |
| Sep 29, 2014 | Late filing | Notification of late filing |
| May 13, 2014 | Late filing | Notification of late filing |
| Sep 26, 2013 | Late filing | Notification of late filing |
| May 15, 2013 | Late filing | Notification of late filing |
| Feb 14, 2013 | Late filing | Notification of late filing |
| Nov 13, 2012 | Late filing | Notification of late filing |
| Sep 27, 2012 | Late filing | Notification of late filing |
| May 15, 2012 | Late filing | Notification of late filing |
| Feb 14, 2012 | Late filing | Notification of late filing |